Akalux

Indicated For

head and neck cancer

About This Medication

# Akalux (cetuximab sarotalocan) Patient Guide: How to Get Treatment at Low or No Cost **Important Note:** Akalux (cetuximab sarotalocan) is currently approved only in Japan for unresectable locally advanced or recurrent head and neck cancer, used with the BioBlade Laser System under Rakuten Medical's Illuminox platform. Outside Japan, including the US, it remains investigational and is not FDA-approved. No standard US prescription assistance program exists. Patients may explore Rakuten Medical's Expanded Access Program (EAP) for potential access to this investigational therapy.[1][2][5] ## About Akalux (cetuximab sarotalocan) Akalux is a targeted cancer therapy combining **cetuximab** (a monoclonal antibody that binds to EGFR on cancer cells) with **sarotalocan** (a photoactivating dye). Administered as an IV infusion (250mg dose), it is activated by non-thermal light from the BioBlade Laser System, causing rapid, selective destruction of targeted cancer cells while sparing healthy tissue. This photoimmunotherapy approach, developed on the Illuminox platform, may also stimulate the immune system against cancer.[1][2][4] Approved in Japan in September 2020 under the Sakigake fast-track and Conditional Early Approval, it treats specific head and neck cancers. Global Phase 3 trials (e.g., ASP-1929-381 Eclipse) are ongoing, testing it with Keytruda for recurrent head and neck cancer, with US approval potentially post-2028.[3][5] Costs in Japan include ~$35K for 4 vials, plus laser components (~$0.3K rent, $17/needle, $2K/diffuser, varying by patient).[6] **Who it's for:** Patients with serious, treatment-resistant head and neck cancers where standard options fail.[1][2] ## Who Qualifies for Access No traditional patient assistance program (PAP) with income-based free medication exists for Akalux in the US, as it's investigational. Instead, Rakuten Medical offers an **Expanded Access Program (EAP)** for patients with **serious or life-threatening** conditions lacking alternatives.[2] ### Key EAP Eligibility Criteria - Serious/life-threatening disease (e.g., advanced head and neck cancer). - No comparable approved treatments available. - Unable to join ongoing clinical trials. - Potential benefits outweigh known risks, based on clinical evidence. - Won't disrupt product development or approval. - Available in countries expecting future commercial approval (e.g., US). - Physician has product training and experience.[2] EAP is physician-initiated, not direct patient enrollment. Speak to your oncologist.[2] ## Income Eligibility Breakdown **No specific income thresholds apply**, as EAP is not income-based like US PAPs (e.g., those at 400-500% FPL). It's case-by-case for compassionate use, prioritizing medical need over finances. If commercialized, future PAPs might follow standards like: | Household Size | Example Threshold (400% FPL, 2026 est.) | Notes | |---------------|---------------------------------------|-------| | Individual | ~$60,000/year | Hypothetical; EAP not income-tied. | | Couple | ~$81,000/year | Check annual FPL updates. | | Family of 3 | ~$102,000/year | N/A for current EAP. | | Family of 4 | ~$123,000/year | Rakuten may develop PAP post-approval. | FPL data from HHS.gov (adjusted for 2026). EAP focuses on clinical urgency.[2] ## Insurance Requirements **Insurance not required for EAP**, but Medicare/Medicaid/coverage may influence access. EAP provides investigational product free if approved, but patients cover administration, monitoring, and laser use costs. Commercial insurance might reimburse off-label/investigational use variably; Medicare Part B denies most unapproved therapies. Discuss with your provider; EAP won't interfere with insurance claims.[2][6] ## Step-by-Step Application Process 1. **Consult your oncologist:** Confirm Akalux suitability for your head/neck cancer. Ensure no trial eligibility.[2][3] 2. **Physician submits request:** Doctor emails Rakuten Medical's Global Medical Affairs at the provided contact (from rakuten-med.com) with patient details, medical history, and rationale.[2] 3. **EAP Committee Review:** Case-by-case assessment (days to weeks). Must meet all criteria; physician needs training.[2] 4. **Approval & Compliance:** If approved, physician handles regulatory submissions (e.g., IRB, informed consent), safety reporting, and product training.[2] 5. **Treatment Begins:** IV infusion + laser activation per protocol. Continued access possible post-trial.[2] Patients cannot apply directly—**physician must lead**.[2] ## Timeline and Delivery - **Review Time:** Variable, typically 2-4 weeks, depending on completeness.[2] - **Setup:** Additional weeks for IRB/ethics approval and training. - **Delivery:** Rakuten ships investigational product to qualified sites. Administered outpatient/inpatient at specialized centers with laser capability.[2][4] - **Full Start:** 1-2 months post-request if approved. ## Alternatives if Denied or Ineligible - **Clinical Trials:** Check clinicaltrials.gov for Phase 3 studies (e.g., Akalux + Keytruda; est. completion 2028).[3] - **Approved Therapies:** Keytruda, Opdivo, or EGFR inhibitors for head/neck cancer; consult NCCN guidelines. - **Other PAPs:** For standard drugs, NeedyMeds.org or PAN Foundation. - **Financial Aid:** Hospital charity care, state programs, or crowdfunding. - **Biosimilars:** None listed for Akalux (unique conjugate).[ ] ## Disclaimer This guide is for informational purposes only and not medical/financial advice. Akalux is investigational outside Japan; efficacy/safety unproven in US. EAP not guaranteed; decisions by Rakuten Medical. Consult healthcare providers. Info based on public sources as of 2026; verify at rakuten-med.com. Rakuten Medical not liable for use.[1][2][5] (Word count: 1028)

Program information last verified: March 25, 2026